Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of PDE4 inhibitor in preparation of medicine for inhibiting glioma proliferation

A glioma and inhibitor technology, applied in the field of anti-tumor drugs, especially glioma drugs, can solve problems such as no research and verification, and achieve the effects of small side effects, good development and application prospects, and strong specificity

Active Publication Date: 2021-10-22
GUANGZHOU HUAZHEN PHARM CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the process of further expanding the PDE4 inhibitor to treat PDE4-related diseases, whether it is effective for other cancers, such as glioma, has not been verified by any studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PDE4 inhibitor in preparation of medicine for inhibiting glioma proliferation
  • Application of PDE4 inhibitor in preparation of medicine for inhibiting glioma proliferation
  • Application of PDE4 inhibitor in preparation of medicine for inhibiting glioma proliferation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: The effect of ZL-n-91 on the inhibition of glioma cell proliferation was detected by CCK8 method.

[0032] 1) Take the glioma cells U87, snb19, and U251 in the logarithmic growth phase to prepare a single cell suspension. 100 μL cell suspension per well (containing 2~3×10 3 cells) were inoculated in a 96-well plate, and were divided into 9 groups: complete cell control group, solvent control group 0 μM, 25 μM, 50 μM, 100 μM, 200 μM, 250 μM, 300 μM, 400 μM, 500 μM, 600 μM, 800 μM, 3 in each group Auxiliary hole;

[0033] 2) 24 hours after plating, after the cells were completely adhered to the wall, different concentrations of ZL-n-91 were added to each group, and the cells were cultured for 48 hours;

[0034] 3) Add 10ul of CCK-8 solution to each well to avoid air bubbles;

[0035] 4) Continue to incubate the cells for 1-2 hours, take out the culture plate, and measure the absorbance of the cells at 450 nm with a microplate reader. And calculate the cell ...

Embodiment 2

[0037] Embodiment 2: Flow cytometry detects the impact of Zl-n-91 on the distribution of glioma cell cycle

[0038] 1) Take U87, snb19, and U251 cells in the logarithmic growth phase, resuspend them with serum-free basal medium, and use 2*10 5 cells / ml were inoculated in 6-well culture plates, cultured in an incubator, and starved for 24 hours;

[0039] 2) After 24 hours, add serum and test drug concentration ZL-n-91 (150 μM, 200 μM) respectively, and set a solvent control group at the same time, and continue to culture the cells for 24 hours;

[0040] 3) After 24 hours, the cells were collected, washed twice with pre-cooled PBS, and prepared into 1×10 cells with PBS. 6 cells / mL of cell suspension, add 1ml of 70% absolute ethanol, and fix at 4°C or -20°C for more than 24h;

[0041] 4) Centrifuge, wash twice with cold PBS, add 500 μL of PE staining according to the kit instructions, gently vortex the cells, incubate at room temperature in the dark for 15 minutes, test on the ...

experiment example 3

[0043] Experimental Example 3: Detection of Zl-n-91's Induction of Apoptosis in Glioma Cells by Flow Cytometry

[0044] 1) Take U87, snb19, U251 glioma cells in the logarithmic growth phase, and use 1.5-2*10 5 cells / ml inoculated in 6-well culture plate;

[0045] 2) 24 hours after plating, after the cells are completely adhered to the wall, add the experimental concentration of ZL-n-91 (150 μM, 200 μM, 300 μM) respectively, and set a solvent control group at the same time, and continue to culture the cells for 48 hours;

[0046] 3) Harvest the cells after 48 hours, wash twice with pre-cooled PBS, and prepare 1×10 cells with 1×Binding Buffer 6 cells / mL cell suspension, take 100 μL in the flow tube, add 5uL 7-AAD and 5uL PE staining according to the kit instructions, gently vortex the cells, incubate at room temperature in the dark for 15min, then add 200uL 1×Binding Buffer to the tube In the middle, the flow cytometric detection was carried out within 1 h, and the results wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a phosphodiesterase 4 inhibitor ZL-n-91 in preparation of a medicine for treating glioma, particularly glioblastoma. An in-vitro cytology experiment shows that the phosphodiesterase 4 inhibitor ZL-n-91 can obviously inhibit proliferation of glioma cell strains in a dose-dependent manner, retard a cell cycle and induce cell apoptosis; an in-vivo animal model shows that the ZL-n-91 can obviously inhibit the growth of subcutaneous glioma, so that the ZL-n-91 has a good development and application prospect.

Description

technical field [0001] The application belongs to the field of antitumor drugs, especially glioma drugs. Specifically, the application provides the application of PDE4 inhibitor ZL-n-91 in the preparation of drugs for treating glioma proliferation. Background technique [0002] Central nervous system cancer (CNS) has been one of the top ten malignant tumors with high morbidity and mortality in my country. In 2016, there were 106,207 new cases of central nervous system (CNS) cancers and 59,120 deaths in China, which is the country with the largest number of new cases and deaths of CNS cancers in the world. my country has a long way to go in the prevention and treatment of CNS cancers. The most common primary CNS cancers are glioma, a malignant tumor of glial cells, which is divided into 4 grades according to its malignancy (WHO grades I to IV), glioblastoma (GBM, grade IV) It is the most common, most malignant and most invasive tumor among gliomas, accounting for the majorit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/341A61P35/00
CPCA61K31/341A61P35/00
Inventor 赵子建李玉玉李芳红赵正刚毛萍周素瑾李美蓉张馨丹
Owner GUANGZHOU HUAZHEN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com